INTRODUCTION
Among the many complications of type 2 diabetes mellitus (T2DM) arising from prolonged hyperglycemia, as well as from comorbid conditions such as hypertension, is chronic kidney disease (CKD), which is present in up to 40% of patients with T2DM [1] .
Glycemic control reduces the incidence and progression of microvascular complications of diabetes [2, 3] , but achieving adequate glycemic control in patients with kidney disease can be challenging. This challenge may be underappreciated in patients with mild impairment in kidney function, who account for around 38% of patients with T2DM [4] . The routine reporting of estimated glomerular filtration rate (eGFR) by clinical laboratories, most commonly using the Modification of Diet in Renal Disease (MDRD) equation [5] , allows clinicians a greater awareness of patients' level of renal function and a greater recognition of even mild impairment. The introduction of sodium glucose co-transporter 2 inhibitors (SGLT2 inhibitors), a class of antihyperglycemic agent with a renal-based mechanism of action, has brought added emphasis to the importance of renal function in choice of treatment for T2DM.
SGLT2 inhibitors demonstrate decreased glycemic efficacy as renal function declines, and this decrement begins in mild renal impairment [6] . Mild renal impairment may be relevant to metformin use as well: metformin is recommended as first-line therapy in most patients [7] , but prescribing guidelines prohibit its use at specific thresholds of serum creatinine levels which correspond to only mild reductions in eGFR in some patients [8] .
In the Fourth National Health and Nutrition Examination Survey (NHANES IV), sulfonylureas were the most commonly used antihyperglycemic agent in those with T2DM and mild CKD, though this was before the introduction of DPP4-inhibitors and other new agents [1] . Sitagliptin is a DPP4-inhibitor which, by preventing degradation of the incretins' glucagon-like peptide-1(GLP-1) and gastric inhibitory polypeptide (GIP), stimulates insulin release in a glucose-dependent manner [9] . Sitagliptin is approved for patients with all stages of CKD [10] ; as sitagliptin is subject primarily to renal elimination [11] , dose adjustment is recommended in patients with moderate-to-severe renal impairment or on dialysis so as to maintain drug exposure similar to that obtained in patients with normal renal function or only mild renal impairment [12] . A substantial number of large clinical studies have demonstrated sitagliptin to be generally safe and well tolerated [13] . In particular, because of the glucose-dependent nature of the insulinotropic effect of sitagliptin, the risk of hypoglycemia associated with use of this therapy is very low, except when used in combination with an agent that induces glucose-independent insulin secretion [14] . ) were identified for this analysis using the MDRD equation to estimate glomerular filtration rate (GFR) [17] . In one of the 3 studies (referred to as Study 3), GFR could be estimated by both the MDRD and the Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) serum creatinine [18] equations. The MDRD equation is imprecise and systematically underestimates GFR at higher levels of renal function [19] . Therefore, to evaluate the accuracy of classification of subject renal function by the MDRD equation (the only method available for Studies 1 and 2), baseline eGFR and renal function classification were evaluated by both equations for all subjects in Study 3 and compared.
METHODS

Data Sources
This was a post hoc analysis of pooled data from subjects who participated in one of three randomized, double-blind trials in which sitagliptin was compared to a sulfonylurea, 10.4 ± 6.5 mg glipizide per day, and 2.0 ± 1.4 mg glimepiride per day in studies 1, 2, and 3, respectively.
As indicated above, the three studies had slight differences in their protocols, including background therapy (i.e., diet/exercise or metformin) and specific sulfonylurea comparator. However, efficacy and safety in both backgrounds are relevant to this analysis. Therefore, because it is not expected that a stable metformin background would impact body weight or hypoglycemic events, and because similar efficacy and side effect profiles of the two second-generation sulfonylureas were expected, data were combined from the three studies in order to increase the power and generalizability of the analysis.
All studies contributing data to the analysis reported here were conducted in accordance with principles of Good Clinical Practice and were approved by the appropriate institutional review boards and regulatory agencies. The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
Analysis Endpoints
Evaluation endpoints were changes from baseline in HbA 1c , fasting plasma glucose 
Statistical Analysis
In each study, the period evaluated began at Analysis of covariance was used to compare the treatment group changes from baseline for the continuous endpoints, at time points indicated. The model controlled for treatment, study, and baseline value. The difference between treatment groups in change from baseline was assessed by testing the difference in the least squares mean change from baseline. Percentages and event rates were assessed using the method of Miettinen & Nurminen [25] , stratified by study to calculate a nominal P value for between-group differences. The event rate was calculated as number of events divided by total subject-years of exposure. The total subject-years of exposure were calculated as the sum, over all subjects, of the time from the first dose to last dose of study medication for the time period included in this analysis.
Using all available data from Study 3, baseline eGFR and mild renal impairment classification using the 4-variable MDRD equation was compared with the baseline values and classification obtained using the CKD-epi creatinine equation, considering CKD-epi eGFR to be the reference value. All analyses were done using SAS (developed by SAS Institute Inc., Cary, NC, USA.), version 9.3.
RESULTS
Of the 1,538 randomized subjects with mild renal impairment across the three studies Baseline demographic and anthropometric characteristics of subjects in the two groups of the pooled study cohort were similar (Table 1) . . The mean duration of T2DM in the cohort was 6.1 years.
Changes from baseline in HbA 1c were similar between the sitagliptin-and the sulfonylureatreated groups (sitagliptin = -0.62%, sulfonylurea = -0.68%; sitagliptin difference from sulfonylurea group 0.06%, P = 0.104; 
DISCUSSION
Tight glycemic control has been shown to reduce the risk of incident renal disease and to slow progression in patients with established renal disease [2, 3] . However, the rates of optimal glycemic control may be lower in patients with mild renal impairment compared to patients without renal disease or with more advanced disease. For example, in NHANES IV and in a large cohort of individuals at high risk for kidney disease, those individuals with T2DM who had mild CKD had significantly worse glycemic control compared to those who had no CKD or who had moderate or severe CKD [1, 26, 27] . The reasons for these findings are unclear, but may be due to lower levels of higher GFR (e.g., mild renal impairment and normal renal function) [28, 29] . However, in routine clinical practice, the majority of clinical laboratories continue to provide estimated GFR values using the MDRD equation [5, 28] .
In this post hoc analysis of subjects with mild renal impairment, treatment with sitagliptin or sulfonylureas provided similar improvements in glycemic efficacy while there was a significantly higher incidence of AEs of symptomatic hypoglycemia with sulfonylurea compared with sitagliptin. Sulfonylurea treatment was also associated with weight gain compared with weight loss with sitagliptin. The results of this analysis show relative efficacy and secretagogues which act directly on pancreatic beta cells [30] . Sulfonylureas stimulate a release of insulin in a glucose-independent fashion, making them effective antihyperglycemic agents and also increasing the likelihood of hypoglycemia. In contrast, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin acts by stabilizing the DPP-4 substrates, GLP-1 and GIP, both incretin hormones which act in a glucose-dependent manner to increase the secretion of insulin by beta cells [9] . DPP-4 inhibitors are generally considered to be weight neutral, although the mild weight loss observed in several studies of broad populations of patients with T2DM [22] [23] [24] , and in this analysis, may be related to stabilization of GLP-1; activation of the GLP-1 receptor with the GLP-1 agonist liraglutide has been shown to decrease body weight in patients with T2DM [31] . In contrast, weight gain with sulfonylureas is a known potential side effect which may result from increased insulin levels [32] . Patients with diabetes and comorbid mild CKD represent a population at increased risk for progression to end-stage renal disease and for cardiovascular events compared to patients with diabetes without renal disease [33] . 
